Nutex Health (NUTX) Stock: Buy, Sell, or Hold?
NUTX - Nutex Health Inc. Common Stock
$216.50
4.19 (1.97%)
▲
5d:
-1.64%
30d:
+12.76%
90d:
+11.86%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 18, 2026
Get Alerted When NUTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NUTX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NUTX shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$379.94
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$235.91
8.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NUTX is currently trading at $216.50, which is considered extended relative to its 30-day fair value range of $191.84 to $213.02. The stock's valuation (Forward PE: 7.6) is in line with its historical norms (7.0). At these levels, the market is pricing in 2.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NUTX is in a strong uptrend. The price is approaching resistance at $222.13. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NUTX scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $288.20 (+35.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NUTX is in a strong uptrend. The price is approaching resistance at $222.13. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NUTX scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $288.20 (+35.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$191.84 -
$213.02
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
29.5%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 35.7% below Wall St target ($288.20)
- NEUTRAL: Market pricing in 2.7% annual earnings growth - fairly valued
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$191.84 -
$213.02
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$198.25
Resistance Level
$222.13
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.62
Wall Street Target
$288.20
(+35.7%)
Revenue Growth (YoY)
-13.6%
Earnings Growth (YoY)
95.9%
Profit Margin
21.2%
Valuation Premium vs History
+2.7% premium
PE vs Historical
7.6 vs 7.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.7%
(market-implied from PE analysis)
1-Year Target
$218.04
(+3%)
2-Year Target
$223.93
(+6%)
3-Year Target
$229.98
(+8%)
3-Yr Target (if PE normalizes)
(PE: 8→7)
PE COMPRESSION
$211.34
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 28.1%)
$573.39
(+170%)
Base:
(SPY PE: 7.6, Growth: 28.1%)
$214.10
(+1%)
Bear:
(PE: 6.5, Growth: 28.1%)
$181.99
(-14%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (8x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 8.20 | Current EPS (TTM): $25.80
Bull Case
$251.53
(+19%)
Analyst growth 8.0%, PE expands to 9.0
Base Case
$228.66
(+8%)
Market implied 8.0%, PE stable at 8.2
Bear Case
$143.93
(-32%)
Severe decline -20.0%, PE contracts to 7.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 4:58 PM ET
Data refreshes hourly during market hours. Next update: 5:58 PM
Data refreshes hourly during market hours. Next update: 5:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
22 analysts |
$285 | 61 BUY |
|
HCA
HCA Healthcare, Inc. |
BUY
25 analysts |
$454 | 48 HOLD |
|
EHC
Encompass Health Corp |
STRONG BUY
12 analysts |
$148 | 55 HOLD |
|
ADUS
Addus HomeCare Corporati… |
STRONG BUY
11 analysts |
$134 | 67 BUY |
|
OPCH
Option Care Health Inc |
STRONG BUY
10 analysts |
$29 | 62 BUY |
